n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, September 14th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

MamaMancini's Holdings, Inc. (MMMB)

TheMicrocapNews, TaglichBrothers, Stock News Now, SmallCapVoice, Marketbeat, and OTC Markets Group reported earlier on MamaMancini's Holdings, Inc. (MMMB), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

MamaMancini's Holdings, Inc. is a marketer of specialty pre-prepared, frozen, and refrigerated all natural food products (as defined by the United States Department of Agriculture - USDA). The Company is a marketer and distributor of a line of beef meatballs and turkey meatballs all with sauce, five cheese stuffed beef and turkey meatballs all with sauce, original beef and turkey meatloaves, chicken parmesan, stuffed peppers, and other like Italian cuisine products. MamaMancini’s Holdings is headquartered in East Rutherford, New Jersey.

MamaMancini's distribution channel includes major retailers and distributors, including Costco, Publix, Shop Rite, Jewel, Save Mart, Lucky's, Lunds and Byerlys, SuperValu, Safeway, Albertsons, SpartanNash, Bashas, Whole Foods Market, Hy-Vee, Sam's Club, and Shaw's. Major retailers and distributors also include Kings, Roche Bros., Key Foods, Stop & Shop, Giant, Giant Eagle, Foodtown, Kroger, Shoppers, King Kullen, Lowes, Central Market, Weis Markets, Ingles, Food City, The Fresh Market, Sysco, Burris Foods, C&S, and Driscoll Foods.

In addition, the Company sells an assortment of its products on air and online on QVC, which is the world's largest direct to consumer marketer.

MamaMancini's offers Slow Cooked Italian Sauce and Meatballs, Stuffed Meatballs, Slow Cooked Sauces, Slow Cooked "Italian Style Sauce" and Meatballs - Gluten Free, Slow Cooked Italian Sauce and Meatballs made without Antibiotics, bacon gorgonzola beef meatloaf, and its Italian Style Meatloaf. It also has Food Service offerings and offers Bulk Deli Orders. 

In August, MamaMancini's Holdings announced that it signed a Letter of Intent (LOI) to acquire Joseph Epstein Food Enterprises, Inc. (JEFE), a manufacturer of food products, which has been the sole manufacturer of MamaMancini’s products since inception. Under the agreed terms, no cash would be exchanged between the parties. JEFE is currently owned by the Chief Executive Officer and President of MamaMancini's Holdings, who in total owns roughly 44 percent of the Company's common stock.

Yesterday, MamaMancini's Holdings announced financial results for Q2 of fiscal year 2018, ended July 30, 2017. Q2 of fiscal year 2018 Revenue increased 69 percent to $7.0 million versus $4.1 million in the previous year period. Net Income for the second quarter was $24,000 in comparison to a Net Loss of $(277,000) in the previous year period. This represents a $301,000 improvement.

Net Loss available to common stockholders was $(5,000), or $0.00 per diluted share, during Q2 of fiscal 2018, versus a Net Loss of $(324,000), or $(0.01) per diluted share in the same quarter the year prior.

Today, MamaMancini's Holdings announced that its Beef and Turkey Stuffed Meatballs were voted by the QVC Shopping Network audience as the #1 product in the 'Quick and Easy Meals' category during QVC's 2017 Audience Choice Awards Program, yesterday September 13, 2017.

MamaMancini's Holdings, Inc. (MMMB), closed Thursday's trading session at $1.09, down 0.91%, on 13,950 volume with 22 trades. The average volume for the last 60 days is 10,618 and the stock's 52-week low/high is $0.31/$1.20.

RenovaCare, Inc. (RCAR)

Zacks, Insider Financial, and MarketWatch reported on RenovaCare, Inc. (RCAR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

RenovaCare, Inc. is developing first-of-their-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the body’s largest organ, the skin. RenovaCare is the developer of the patented CellMist™ and SkinGun™ technologies. These are for isolating and spraying a patient’s own stem cells onto burns and wounds for fast self-healing.  RenovaCare has its corporate headquarters in New York, New York. 

The Company’s flagship technology, the CellMist™ System, employs its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds. RenovaCare is developing its CellMist™ System as a promising new option for patients suffering from burns, chronic and acute wounds, and also scars. The CellMist™ System targets patients globally who suffer burns, chronic and acute wounds, acne scarring, and skin defects and diseases such as vitiligo. 

In investigative clinical use in the U.S., SkinGun™ treatments have shown the potential to naturally and rapidly heal burns and other serious wounds. Based on preliminary case studies, CellMist™ System patients can be treated within 90 minutes of entering an emergency room. A patient’s stem cells are isolated, processed, and sprayed onto wound sites for fast healing. 

RenovaCare has a partnership to validate the science behind its pioneering technology for treatments of wounds, burns, and other skin defects. Its research partner is Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charité - Universitätsmedizin Berlin, one of the world’s largest university hospitals. 

RenovaCare announced in December of 2016 that it bolstered its patent portfolio with the issuance of a U.S. patent for its novel SkinGun™ device. The United States Patent and Trademark Office (USPTO) granted an additional 30-month extension for the patent, providing protection beyond the year 2035. The issuance of the U.S. patent reinforces the Company’s current patent protections in Germany. 
  
Recently, RenovaCare announced that its approach to isolating a patient’s own stem cells for subsequent spray onto burns and wounds was validated by researchers in ‘Differentiation’, a foremost peer-reviewed scientific publication. According to their findings, the methodology, which has been adopted by RenovaCare, successfully isolates those specific cell populations with the greatest regenerative capacity to support the growth of fully-functioning skin.

Mr. Thomas Bold, RenovaCare’s President and Chief Executive Officer, said, “It’s very exciting to have this scientific validation that our approach is ideal for rapid and natural skin regeneration. We’ve always had confidence that our methodology isolates the body’s most regenerative cell population before spray application with our ultra-gentle SkinGun™.”

RenovaCare, Inc. (RCAR), closed Thursday's trading session at $3.47, up 5.15%, on 4,268 volume with 18 trades. The average volume for the last 60 days is 13,461 and the stock's 52-week low/high is $0.6815/$6.35.

Giggles N' Hugs, Inc. (GIGL)

SeriousTraders, Tip.us, RedChip, OTCJournal, StocksToBuyNow, SmallCap Network, Investor's Insight, RedChip, SmallCapVoice, and Money and Markets reported on Giggles N' Hugs, Inc. (GIGL), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Giggles N' Hugs, Inc. is the owner and operator of family-friendly restaurants. These restaurants bring together high-end, organic food with active, leading-edge play and entertainment for children. The Company features high-quality menus made from fresh and local foods. Established in 2010, Giggles N' Hugs is headquartered in Los Angeles, California. 

Each Giggles N' Hugs location offers an upscale, family-friendly atmosphere with a dedicated play area for children 10 and younger. Additionally, the Company features nightly entertainment. This includes magic shows, concerts, puppet shows, and face painting, and party packages for families. 

Membership at Giggles N' Hugs comes with benefits. These include first access to its special kids’ events, monthly deals, and unlimited visits for the whole family. The Company was voted the #1 birthday party place in Los Angeles by Nickelodeon. Moreover, it was voted "Best Pizza in Los Angeles" by Nickelodeon.

Giggles N' Hugs was also listed best family & kid-friendly restaurants by CitySearch and GoCityKids. The Company has locations in Century City, Topanga, and Glendale, California.  

Giggles N’ Hugs has engaged PacificShore Ventures to explore potential synergistic acquisition opportunities. PacificShore is an international specialty finance and Mergers & Acquisitions (M&A) firm. 

Giggles N' Hugs is targeting companies, which are cash flow positive and have minimum annual revenue of $5 million or more. PacificShore will work to identify and create target company profiles, introduce, initiate negotiations, and ultimately facilitate the closing of such potential companies and introduce traditional banking relationships for Giggles N' Hugs to finance the acquisitions. 

Giggles N’ Hugs announced in May 2017 that it signed a non-binding Letter of Intent (LOI) with City Scape trading (franchisee), a Bahrain-based hospitality company, to open up to two Giggles N’ Hugs franchise locations in Bahrain with additional locations to come if successful. With this master license agreement, Giggles N’ Hugs will receive up-front development fees for each location, and also an ongoing royalty based on a percentage of monthly gross sales.

Giggles N’ Hugs announced in June that its Global Brand Ambassador, Jillian Michaels, would launch Fitness Friday programs and introduce healthy new menu items for the Company’s locations. Jillian Michaels is a world-renowned wellness expert, business entrepreneur, and mom.

Recently, Giggles N’ Hugs announced its financial performance for Q2 ended July 2, 2017. Q2 highlights include same store Net Sales for its Glendale location increasing 4.3 percent year-over-year. Same store Net Sales for its Topanga location increased 5.0 percent year-over-year.

The Company’s Cost of Operations decreased 41.5 percent year-over-year to $429,164. Its Loss from Operations improved 46.2 percent year-over-year. The Glendale location produced record positive cash flow of more than 35 percent at the unit level.

Giggles N' Hugs, Inc. (GIGL), closed Thursday's trading session at $0.0242, up 0.83%, on 903,637 volume with 46 trades. The average volume for the last 60 days is 723,220 and the stock's 52-week low/high is $0.0018/$0.26.

Spindle, Inc. (SPDL)

TopPennyStockMovers and SmallCapVoice reported previously on Spindle, Inc. (SPDL), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Spindle, Inc. (dba CATALYST Commerce Solutions) is an emerging provider of integrated marketing and commerce solutions focused on the Small and Medium-sized Business (SMB) market. The Company is an innovator of merchant and consumer-facing commerce solutions. It is concentrating on pioneering new ways for businesses to quickly integrate mission critical business services, payment acceptance, and mobile marketing services. This is while empowering location-based merchant discovery, fulfillment, and frictionless consumer engagement. OTCQB-listed, Spindle is headquartered in Mesa, Arizona. 

The CATALYST Marketing System components and CATALYST IP were included in the asset acquisition from Catalyst Business Development, Inc. that Spindle completed in 2015. Catalyst Business Development is a Scottsdale, Arizona-based provider of payment gateway services, sales, and software solutions.

Spindle's commitment is to provide innovative solutions that surpass traditional boundaries, and allow clients, partners, merchants, and consumers to take full advantage of the fast-developing mobile economy. Spindle is focusing on payment processing services and integrating value-added capabilities that enhance merchant revenue and increase consumer loyalty, experience, and retention. 

The Company integrates acceptance channels. Spindle is also pushing the boundaries through adding big data collection, analytics, marketing, loyalty and points programs and integration with other domains (including security systems and business automation products). Regarding Point-Of-Sale (POS) & MPOS, Spindle has a POS solution built around the power of the cloud. This is for restaurants and retail to mobile vendors and event organizers. 

Spindle acquired Yowza!! - a provider of mobile couponing technology. This technology is integrated with Spindle's platform. Spindle signed distribution agreements with a broad array of channel partners. Via these relationships, it can provide wide-ranging mobile commerce services through many channels. These channels include wireless providers, vending services operators, and technology solutions providers. 

Spindle has finalized an agreement to acquire specific digital marketing software assets from CoverCake, Inc., specifically CoverCake's intelligent algorithms for data mining and consumer engagement. CoverCake's software is envisioned to enhance the sophistication and proprietary strengths of Spindle's CATALYST Platform. CoverCake's software capabilities include intelligent content aggregation; data mining on different social media data feed platforms, and a strong Content Management System (CMS) backend. 

Spindle has executed two strategic agreements with Concourse Team Express. With this strategic relationship, Team Express will use the CATALYST Team Sports Platform to offer teams the ability to manage their rosters, collect fees, integrate social media, team scheduling, statistics, location directions, and more. CATALYST Team Sports will be adding the Team Express custom teamwear and team store solutions to the platform. Team Express is a top multi-channel internet retailer.

This past June, Spindle announced the launch of the CATALYST Marketing System. The platform has been further enhanced through integrating the Company's customized CATALYST software with solution providers, the CATALYST Gateway, and its recently acquired software from CoverCake. The CATALYST Marketing System (CMS) enables SMBs the ability to manage their business from one central hub. 

Spindle, Inc. (SPDL), closed Thursday's trading session at $0.15, down 5.54%, on 144,200 volume with 19 trades. The average volume for the last 60 days is 43,466 and the stock's 52-week low/high is $0.046/$0.30.

BioSig Technologies, Inc. (BSGM)

DreamTeamNetwork, The Wall Street Transcript, Goldman Small Cap Research, PennyStockLocks, Stock Commander, SeeThruEquityResearch, Stock News Now, ResearchOTC, StockRockandRoll, Wall Street Resources, Pumps and Dumps, and BUYINS.NET reported on BioSig Technologies, Inc. (BSGM), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

BioSig Technologies, Inc. is a medical device company developing PURE EP™ -a proprietary technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures. The Company’s aim is to seek Food and Drug Administration (FDA) 510(k) approval for the PURE EP™ System. It is preparing to commercialize the PURE EP™ System. BioSig Technologies has an office in Los Angeles, California centered on research and development (R&D). The Company is headquartered in Minneapolis, Minnesota.  

BioSig Technologies’ PURE EP™ is a next-generation surface electrocardiogram and intracardiac multichannel signal acquisition and analysis system. The design of it is to help electrophysiologists in making clinical decisions in real-time through acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data, which may be utilized to guide the electrophysiologists in identifying ablation targets (areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia)). 

The Company has attained proof of concept validation and tested its prototype at the University of California at Los Angeles (UCLA) Cardiac Arrhythmia Center. It has performed pre-clinical studies at Mayo Clinic in Minnesota. Furthermore, it is collaborating with other prestigious cardiac arrhythmia centers. These include Texas Cardiac Arrhythmia Institute, UH Case Medical Center in Cleveland, Ohio, and Mount Sinai Medical Center in New York. 

BioSig Technologies’ plan is to transition from pre-clinical evaluation of the PURE EP to product development. It expects to fully develop a Quality Management System. It signed a product development collaboration agreement with expert Mayo Clinic cardiac electrophysiologists.  Company Management is now involved with regulatory agencies in the U.S. and Europe to secure clearance to sell the PURE EP System domestically and internationally. 

BioSig has also expressed its intention to enter the developing field of bioelectric medicine. Also, the Company has partnered with Minnetronix on technology development. BioSig is working toward FDA 510(k) clearance and CE Mark for the PURE EP System.

Recently, BioSig Technologies announced that it engaged Health Research International (HRI) to compile essential market data and help perform strategic planning for its PURE EP platform technology. Project goals include understanding and presenting the clinical relevance of the Company’s technology, pricing strategies, and envisioning optimal applications of its platform technology beyond EP.

BioSig will benefit from HRI’s acknowledged research expertise. Additionally, it will gain access to HRI’s wide-ranging network in the medical field. Therefore, this collaboration will provide further meaningful input concerning new products, technologies, and clinical applications, as BioSig moves closer to the commercialization of the PURE EP System.

BioSig Technologies, Inc. (BSGM), closed Thursday's trading session at $1.25, down 0.79%, on 25,038 volume with 35 trades. The average volume for the last 60 days is 19,311 and the stock's 52-week low/high is $1.20/$2.00.

graphic

The QualityStocks
Company Corner

graphic
graphic

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.6699, up 11.65%, on 96,237 volume with 51 trades. The stock’s average daily volume over the past 60 days is 59,888 and its 52-week low/high is $0.20/$2.09.

ORHub, Inc. (OTC: ORHB), a medical software company focused on delivering case-based data analytics at the speed of surgery, today announces that it has become a Technology Affiliate of the International Consortium for Health Outcomes Measurement ("ICHOM"), a non-profit organization focused on advancing value-based health care through the standardized measurement and reporting of patient outcomes. As demonstrated in a powerful customer review published by Microsoft, ORHub delivers unprecedented intelligence and insight into the volume of cases in an operating room to achieve greatly improved resource allocation, real-time monitoring of surgery, and predictive analysis. Read the full customer review at http://nnw.fm/2iGHh

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub (ORHB) Joins ICHOM TechHub to Propel Value-Driven Improvements in Healthcare

ORHub, Inc. Announces Major Expansion of Operations with Launch and Adoption of Orthopedic Service Lines

ORHub, Inc. Signs National Sales Partner to Launch Transformative Medical Software in Major U.S. Markets

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.35, off by 3.71%, on 583,779 volume with 279 trades. The stock’s average daily volume over the past 60 days is 324,642, and its 52-week low/high is $0.07/$0.72.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. The publication, titled, "Biosynthesis Technology Could Transform Cannabinoid Production," discusses companies providing innovative, cannabinoid biosynthesis processes. To view the full publication, visit: https://www.networknewswire.com/biosynthesis-technology-transform-cannabinoid-production/

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

NetworkNewsWire Announces Publication Highlighting the Potential of Cannabinoid Biosynthesis

NetworkNewsWire Announces Publication Discussing Innovative Drug Developments in the Global Marijuana Market

InMed Files Provisional Patent for Biosynthesis of Cannabinoids

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.05762, off by 7.51%, on 18,944,253 volume with 925 trades. The stock’s average daily volume over the past 60 days is 21,465,668, and its 52-week low/high is $0.0075/$0.415.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

NetworkNewsWire Announces Publication Discussing the Operations of Innovative Cannabis Companies

NetworkNewsWire Announces Publication Highlighting Key Players in Big Pharma M&A

SinglePoint Completes Acquisition of Dr. FeelGood, a Profitable Cannabis Distribution Company

Algae Dynamics Corp. (ADYNF)

The QualityStocks Daily Newsletter would like to spotlight Algae Dynamics Corp. (ADYNF). Today, Algae Dynamics Corp. closed trading at $0.1223, even for the day. The stock’s average daily volume over the past 60 days is 11,803 and its 52-week low/high is $0.0001/$0.62.

Algae Dynamics Corp. (ADYNF) is focused on developing proprietary research and products involving botanical oils derived from cannabis and algae.

The original core of the company's product development strategy was the extraction of Omega-3 fatty acids from certain strains of algae with high concentrations of DHA to create various nutraceutical products. As a result of the many demonstrated health benefits of other botanical oils, most notably cannabis oil, Algae Dynamics developed a strategy aimed at developing products that combined the health benefits of algae and cannabis oils. Capitalizing on the burgeoning demand for cannabis oil and other smoke-free alternatives to marijuana consumption will help support ongoing initiatives to create and market research-driven product formulations.

Although the company is publicly traded in the U.S., business is conducted in Canada with no exposure to U.S. federal regulation involving cannabis. The Canadian cannabis oil extraction marketplace is projected to grow from C$1 million in 2015 to C$1.7 billion in 2020, which is more than a 1,000-fold increase. With the Government of Canada indicating a target date for full legalization on or before July 2018, numerous opportunities for sales in extracts and oils will open up very soon.

Using Colorado as a comparable example, a study performed by Mackie Research Capital found that 45% of dried marijuana users in the state would eventually convert to marijuana extracts and oils. This is because most consumers taking cannabis for medical purposes are increasingly looking for delivery systems that do not involve smoking marijuana. The market's attractiveness can be further realized when considering that the Canada's licensed producer marketplace is far less competitive with 45 current licensed producers for the whole country vs. 624 licensed cultivators in Colorado.

Collaborating with prominent Canadian universities is a core part of the Algae Dynamics' plan to bolster cannabis extraction expertise, develop premium products and add to its portfolio of intellectual property. Through its agreements with the University of Waterloo and the University of Western Ontario, the company is focusing primarily on the use of extracts from cannabis oil and algae oil in the context of cancer as well as the development of new pharmacotherapies for mental health.

Near-term goals include expanding research and development work with existing and new Canadian universities, securing supply/service agreements with licensed producers, and submitting an application to Health Canada to become a licensed producer of medical marijuana and ultimately have a license to sell products derived from cannabinoids. Algae Dynamics also owns a proprietary technology for the cultivation of low cost, highly pure algae biomass, which will be developed as a vertical integration strategy in the future to support the need to source algae oil for research-driven product formulations. The management team leading these initiatives has nearly a century of beneficial experience spanning from management and process experience to successful fund raising and commercialization.

As part of its key objective to be the #1 research Canadian cannabis oil research-driven product formulator, the company has also formed a strong team of scientific and strategic advisors that complement ongoing R&D relationships and initiatives. Individuals who support the company's initiatives include Dr. Jonathan Blay PhD, FRSB, FIBMS, Csci, CBiol, who performs research and product development on cannabis oil and its constituents in the context of colorectum, pancreas, breast and prostate cancers; and Dr. Steven Laviolette, BSc, PhD, who performs research and product development on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety and schizophrenia.

With such a strong foundation laid in the areas being pursued, Algae Dynamics is well positioned to execute on its carefully developed business plan to fast-track to revenue growth while having a longer-term strategy to build a sustainable enterprise-building opportunity in a rapidly expanding market. Disclaimer

Algae Dynamics Corp. Blog

Algae Dynamics Corp. News:

Algae Dynamics Corp Enters Into a Letter of Intent with Bonify to Produce Unique Cannabis Oil Products; Accelerates Go-to-Market Strategy

NetworkNewsWire Releases Exclusive Audio Interview with Algae Dynamics Corp. (ADYNF)

Algae Dynamics Corp. (ADYNF) Engages NetworkNewsWire for Corporate Communications Solutions

Kootenay Zinc Corp. (CSE:ZNK) (OTCQB:KTNNF)

The QualityStocks Daily Newsletter would like to spotlight Kootenay Zinc Corp. (KTNNF). Today, Kootenay Zinc Corp. closed trading at $0.063, even for the day. The stock’s average daily volume over the past 60 days is 23,916, and its 52-week low/high is $0.007/$0.59.

Kootenay Zinc Corp. (KTNNF) is a mineral exploration and development company focused on discovering large-scale sedimentary-exhalative ("SEDEX") zinc deposits. Based in Vancouver, British Columbia, the company is ideally positioned near its primary target, the Sully Property, located 18 miles east of the world-class Sullivan Mine.

Of the 22 raw materials tracked by the Bloomberg Commodity Index, zinc was the best-performing base metal in 2016. Based on a widening global supply deficit, outlook for the commodity remains strong. As the most closely tied base metal to the Chinese economy, zinc demand and prices are expected to rise well into the year 2020, putting increased pressure on zinc supply.

For 2017, Goldman Sachs has predicted a 360,000 ton shortage of zinc, along with a subsequent rise in zinc prices to $2,500 per metric ton in the first half of the year. Zinc continues to make history in the metals exchange, driving significant interest in the market amid supply constraints in concentrates and refined metal drive prices.

Ready to claim its share of the market, Kootenay Zinc is focused on its Sully Property. It comprises 1,375 hectares and overlies rocks of similar age and origin as those which host the legendary Sullivan deposit. The Sullivan mine was discovered in 1892, and is known to be one of the world's largest SEDEX deposits. Over its 100-year lifetime, Sullivan produced approximately 150 million tonnes of ore, including approximately 300 million ounces of silver, 8 million tonnes of zinc and 8 million tonnes of lead.

Notably, geophysical data suggests that Kootenay Zinc's Sully project and Sullivan share many geological features:

  • Strata at Sully are in the same sedimentary basin as the Sullivan mine
  • The exact stratigraphic time horizon at which Sullivan formed is present at Sully
  • Filtered AeroMag anomalies coincident with Sullivan Time at Sully appear similar to Sullivan
  • Gravity anomaly at Sully indicates excess mass of comparable magnitude to Sullivan
  • Pb-Zn is present as traces in outcrop, drill core and in a soil geochemical anomaly

The squeeze in zinc supplies particularly affects China, which is both the world's largest zinc consumer and its largest producer, with 4.9 million tons of output in 2015. Chinese manufacturers are now being forced to import zinc for use in cars, household appliances, paints, rubber products and smartphones.

Zinc's rally shows no sign of slowing down in the near future, and companies that currently occupy stake in a zinc deposit find themselves in an enviable position over miners rushing to find new reserves. With its Sully Project, Kootenay Zinc could be on track to capture its share of the market, guided by a management team of mining directors and executives that currently lead some of the world's best mining companies and have been involved in world-class discoveries which sold for billions of dollars. The company's technical team includes industry experts that have worked on mega-mining projects, including the Sullivan and Voisey Bay projects. Disclaimer

Kootenay Zinc Corp. Company Blog

Kootenay Zinc Corp. News:

Sully Project - E3 Target Drilling Underway

Kootenay Zinc Corp.: Sully Project Exploration Update

NetworkNewsWire Releases Exclusive Audio Interview with Kootenay Zinc Corp. (KTNNF)

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

OTCtipReporter
(EFCT) +337.50%

2.

MarketClub Analysis
(ALDX) +70.08%

3.

KingPennyStocks
(OBMP) +47.84%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251